WO2001005376A1 - Nouvelle formulation pharmaceutique - Google Patents
Nouvelle formulation pharmaceutique Download PDFInfo
- Publication number
- WO2001005376A1 WO2001005376A1 PCT/SE1999/002474 SE9902474W WO0105376A1 WO 2001005376 A1 WO2001005376 A1 WO 2001005376A1 SE 9902474 W SE9902474 W SE 9902474W WO 0105376 A1 WO0105376 A1 WO 0105376A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation according
- solubihzer
- felodipine
- formulation
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the present invention relates to a pharmaceutical extended release formulation of felodipine, and to methods of prepa ⁇ ng such a formulation
- the object of this invention is to obtain a solid formulation with good bioavailabihty and extended release of the active substance
- Felodipine is a drug having very low solubility
- Felodipine is commonly classified as a calcium antagonist, which are widely used for the treatment of cardiovascular disorders such as lschaemic heart disease and arte ⁇ al hypertension Felodipine has a solubility of only 0 5 mg/1 in water at 25 °C
- the extended release preparation delivers the amount of drug needed to maintain an adequate and even effect du ⁇ ng the entire therapeutic dosage interval This usually means that the drug should be delivered at a constant rate to give an even concentration of administered drug in the blood This is of specific importance for drugs having a small therapeutic index, that is a small difference between effective and toxic concentration
- a delayed and constant release of the drug will also be of importance for locally lr ⁇ tating drugs having potential ⁇ sk of causing gastrointestinal disturbances when present m large local concentrations or for drugs having a short elimination half-life In the latter case a less frequent administration and thus better patient compliance (cf Hayes R B et al Clm Pharm Ther (1977), 22, p 125-130) may be obtained with extended release preparations compared with conventional dosage forms
- a drug in extended release form is generally given via the oral route
- the preparations should preferably give an extended and reproducible release of drug and cont ⁇ bute to a reproducible absorption, have no toxic or lr ⁇ tating constituents and be suitable also for high dosage drugs
- extended release is achieved by controlling dissolution and/or diffusion of medicament from the dosage form
- mate ⁇ als e g waxes, fatty mate ⁇ als, polymers, natural, synthetic and semisynthetic gums
- HPMC hydroxypropyl methylcellulose
- HPMC hydroxypropyl methylcellulose
- the soluble polymer forms a gelatinous layer around the tablet after the exposure of the tablet to gastro-intestmal fluids or saliva
- the relase of the drug is limited by the rate of water penetration into, and diffusion of drug through, the gel formed (Bamba et al Int J Pharm (1979), 2, 307) Erosion of the gel structure is also an important release mechanism of a drug from the system
- the polymers used have to hydrate rapidly in order to protect the tablet from fast dissolution (Alderman 1984)
- the rate of absorption of a drug with very low solubility into the circulation from the intestinal tract is closely related to the rate of dissolution Since a low dissolution rate generally results m a low extent of bioavailabihty it is difficult to decrease the rate of absorption, l e increase the duration, without at the same time lowe ⁇ ng the extent of bioavailabihty
- US 4 803 081 discloses an extended release preparation of an active compound with very low solubility containing the active compound dissolved or dispersed in a serm-sohd or liquid non-ionic solubihzer and whereby the amount by weight of the solubihzer is at least equal to the amount by weight of the active compound Desc ⁇ ption of the invention
- a further object is to provide a formulation that is easy to manufacture
- a still further object of the invention is to provide a formulation that contains a low amount of solubihzer
- the solubihzers suitable according to the invention are defined below
- the active compound is preferably dissolved or dispersed in the solubihzer In the solution the drug is included in a micell-structure formed by the solubihzer
- the mixture of the drug and the solubihzer is incorporated into a pharmaceutical formulation, which gives prolonged release
- the present invention relates to a solid formulation with extended release of felodipine comp ⁇ smg felodipine dissolved or dispersed in a solubihzer selected from the group consisting of a polysorbate, a poloxyethylated glycol monoether, a polyoxyethylated alkyl phenol, a poloxamer, a polyoxyethylene castor oil de ⁇ vative, a polyoxyethylene stearate or another fatty acid ester with PEG, a glyce ⁇ de, a sorbitan ester, and a sucroglyce ⁇ de
- a solubihzer selected from the group consisting of a polysorbate, a poloxyethylated glycol monoether, a polyoxyethylated alkyl phenol, a poloxamer, a polyoxyethylene castor oil de ⁇ vative, a polyoxyethylene stearate or another fatty acid ester with PEG, a glyce ⁇ de, a sorb
- the present invention relates to a process for the preparation of a solid formulation with extended release of felodipine whereby the active compound is dissolved or dispersed in a solubihzer selected from the group consisting of a solid formulation with extended release of felodipine characte ⁇ zed in that it comp ⁇ ses felodipine dissolved or dispersed in a solubihzer selected from the group consisting of a polysorbate, a poloxyethylated glycol monoether, a polyoxyethylated alkyl phenol, a poloxamer, a polyxyethylene castor oil de ⁇ vative, a polyoxyethylene stearate or another fatty acid ester with PEG, a glyce ⁇ de, a sorbitan ester, and a sucroglyce ⁇ de, whereafter the mixture is incorporated into a suitable release controlling system in a known way and formed to a pharmaceutical dosage unit
- a solubihzers suitable for the formulations according to the invention are semi-
- Glycerides (mono-glycerides), e g, Monoolein (Glyceryl monooleate), Capmul, Captex, Imwitor, Gelucire, Myverol etc. See page 207.
- Sorbitan esters - partial esters of sorbitol and its mono- and di-anhydrides with oleic acid, eg Spans etc. See page 473.
- solubihzers are within categories a)-g):
- Chremophor EL Chremophor EL
- RH 40 Chremophor EL
- RH 60 Chremophor EL
- the active compound mixed with the solubihzer is incorporated into different kinds of known controlled release systems, e g a hydrophilic gel system, beads coated with a rate controlling membrane, which can be a diffusion retarding coating or a disintegrating coating or tablets with an inert porous mat ⁇ x
- the solubihzed drug is preferably combined with a hydrophilic gel system, namely a hydrophilic swelling mat ⁇ x e g HPMC
- a hydrophilic swelling mat ⁇ x e g HPMC This form of controlled release mechanism is a suitable ay to control the release of the micelles of drug and solubihzer
- HPMC hvdroxypropyl methylcellulose
- suitable compounds effecting the release of the active compound from the hydrophilic gel system are guar gum, xanthan gum, carboxypolymethylene, different cellulosic mate ⁇ als e g hydroxyethyl cellulose, sodium
- the preparation according to the invention contains 20-80% by weight, preferably 30-50% by weight of the hydrophilic gel system
- HPMC having a hvdroxypropyl content of 4-12% by weight, especially about 8 5% by weight and a viscosity lower than 100 cps.
- e g 6 15 and/or 50 cps The viscosity is measured by a standardized method described e g in United States Pharmacopeia XXI, 1985, p 672
- the final formulation is e g in the form of a gel tablet
- the preparation can be manufactured into a commercially acceptable form, e g a tablet or a hard gelatin capsule comprising the gel forming granulate, that shows unexpectedly good absorption of the actn e compound as well as a prolonged duration of action
- the proportions between the active compound and the solubihzer varies in the range from 1 0 01 to 1 10, preferably in the range from 1 0 1 to 1 8, and most preferably in the range from 1 0 5 to 1 6
- the proportions is preferably in the range from 1 0 01 to 1 1
- controlled release formulations e g tablets with an inert porous mat ⁇ x, capsules comp ⁇ smg granules with a diffusion retarding coating or a disintegrating coating
- the tablets with an inert porous mat ⁇ x are obtained by mixing the drug and solubihzer with water-insoluble polymers or waxes and with fillers and binders Polyvmylacetate, i ) polw mylchlonde, ethylcellulose, paraffin and cellulose acetate phthalate could be used as suitable diffusion-retarding polymers
- the files and binders are solid, powdered earners such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose de ⁇ vative, gelatine or other suitable carrier
- the mixture is moistened with a solvent, e g water or ethanol or a solution consisting of e g water and a polymer e g polyvinylpy ⁇ ohdone
- a solvent e g water or ethanol or a solution consisting of e g water and a polymer e g polyvinylpy ⁇ ohdone
- a lub ⁇ catmg agent e g magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethyleneglycol wax may be added The mixture is then formed to tablets
- the capsules comp ⁇ sing granules with extended release characte ⁇ stics are obtained by making a core material containing the drug and the solubihzer together with fillers The 0 surface of the core is then coated with diffusion-retarding water insoluble polymers or waxes The granules are then filled into hard gelatine capsules
- the core mate ⁇ al could e g be prepared by mixing the drug and the solubihzer with carefully selected fillers such as lactose, sorbitol, starch, cellulose de ⁇ vatives or other suitable fillers
- the mixture is moistened with a solvent, e g water or ethanol or a solution consisting of e g water and a ⁇ polymer e g polyvmylpyrrohdone
- the mass is formed to granules e g by extrusion and spheromzation
- the surfaces of the cores formed are coated with a solution consisting of a solvent e g methylene
- the following examples illustrate the invention In all expe ⁇ ments the formulations were made with different types of polymers and solubihzers
- the polymers used were PEO (polyethylene oxide) with molecular weights of 4,000,000 g/mol (PEO 4 ), 2,000,000 g/mol (PEO 2 ), and 900,000 (PEO 0 9 ), HPMC (hydroxypropyl methyl cellulose) with two different viscosities (60SH50 and 10,000), and HEC (hydroxy ethyl cellulose) of high (HEC HHX), medium (HEC HX), and low (HEC M) molecular weights
- the surfactants used were SDS (sodium dodecylsulfate), CTAB (cetyl t ⁇ methylammomum bromide), Gelucirevgj, and sulfobetaine Filler and lub ⁇ cants were AMS (aluminium magnesium silicate) and SSF (sodium stearyl fumarate)
- the tablets were typically
- Example 9 Formulations of felodipine in HEC HHX with felodipine/surfactant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020007011312A KR20010078703A (ko) | 1999-07-20 | 1999-12-22 | 신규 제약 제제 |
EP99964928A EP1113786A1 (fr) | 1999-07-20 | 1999-12-22 | Nouvelle formulation pharmaceutique |
AU30956/00A AU3095600A (en) | 1999-07-20 | 1999-12-22 | New pharmaceutical formulation |
CA002328102A CA2328102A1 (fr) | 1999-07-20 | 1999-12-22 | Nouvelle formulation pharmaceutique |
JP2001510433A JP2003504392A (ja) | 1999-07-20 | 1999-12-22 | 新規医薬製剤 |
NO20004816A NO20004816L (no) | 1999-07-20 | 2000-09-26 | Ny farmasøytisk formulering |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9902742A SE9902742D0 (sv) | 1999-07-20 | 1999-07-20 | New pharmaceutical formultion |
SE9902742-7 | 1999-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001005376A1 true WO2001005376A1 (fr) | 2001-01-25 |
Family
ID=20416534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1999/002474 WO2001005376A1 (fr) | 1999-07-20 | 1999-12-22 | Nouvelle formulation pharmaceutique |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1113786A1 (fr) |
JP (1) | JP2003504392A (fr) |
KR (1) | KR20010078703A (fr) |
CN (1) | CN1319004A (fr) |
AU (1) | AU3095600A (fr) |
CA (1) | CA2328102A1 (fr) |
NO (1) | NO20004816L (fr) |
SE (1) | SE9902742D0 (fr) |
WO (1) | WO2001005376A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003094895A1 (fr) * | 2002-05-07 | 2003-11-20 | Bernard Charles Sherman | Comprimes a liberation prolongee a base de felodipine |
WO2004028503A1 (fr) * | 2002-09-30 | 2004-04-08 | Universiteit Gent | Systeme a liberation controlee de substances bioactives |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602005010604D1 (de) * | 2004-11-17 | 2008-12-04 | Ares Trading Sa | Benzothiazolformulierungen und ihre verwendung |
CN101103964B (zh) * | 2006-07-14 | 2010-09-29 | 海南盛科生命科学研究院 | 一种含有非洛地平的缓释制剂及其制备方法 |
KR100841877B1 (ko) * | 2006-08-31 | 2008-06-27 | 조선대학교산학협력단 | 국소적으로 가용화 된 난용성 약물의 제어 방출형 제제조성물 및 그의 제조 방법 |
CN102784128B (zh) * | 2012-07-31 | 2015-01-07 | 北京协和药厂 | 一种非洛地平缓释制剂及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4803081A (en) * | 1986-04-11 | 1989-02-07 | Aktiebolaget Hassle | New pharmaceutical preparations with extended release |
EP0315960A1 (fr) * | 1987-11-11 | 1989-05-17 | Euro-Celtique S.A. | Capsule à libération orale instantanée contenant de la nifédipine |
WO1997002017A1 (fr) * | 1995-07-03 | 1997-01-23 | Elan Corporation, Plc | Formulations a liberation lente pour medicaments faiblement solubles |
WO1997039050A1 (fr) * | 1996-04-18 | 1997-10-23 | Edward Mendell Co., Inc. | Systemes d'hydrogels heterodisperses - medicaments amorphes a liberation prolongee |
WO1999021534A1 (fr) * | 1997-10-27 | 1999-05-06 | Merck Patent Gmbh | Solutions a l'etat solide et dispersions de medicaments tres faiblement solubles dans l'eau . |
-
1999
- 1999-07-20 SE SE9902742A patent/SE9902742D0/xx unknown
- 1999-12-22 CN CN99811100A patent/CN1319004A/zh active Pending
- 1999-12-22 EP EP99964928A patent/EP1113786A1/fr not_active Withdrawn
- 1999-12-22 CA CA002328102A patent/CA2328102A1/fr not_active Abandoned
- 1999-12-22 JP JP2001510433A patent/JP2003504392A/ja active Pending
- 1999-12-22 AU AU30956/00A patent/AU3095600A/en not_active Abandoned
- 1999-12-22 KR KR1020007011312A patent/KR20010078703A/ko not_active Application Discontinuation
- 1999-12-22 WO PCT/SE1999/002474 patent/WO2001005376A1/fr not_active Application Discontinuation
-
2000
- 2000-09-26 NO NO20004816A patent/NO20004816L/no not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4803081A (en) * | 1986-04-11 | 1989-02-07 | Aktiebolaget Hassle | New pharmaceutical preparations with extended release |
EP0315960A1 (fr) * | 1987-11-11 | 1989-05-17 | Euro-Celtique S.A. | Capsule à libération orale instantanée contenant de la nifédipine |
US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
WO1997002017A1 (fr) * | 1995-07-03 | 1997-01-23 | Elan Corporation, Plc | Formulations a liberation lente pour medicaments faiblement solubles |
WO1997039050A1 (fr) * | 1996-04-18 | 1997-10-23 | Edward Mendell Co., Inc. | Systemes d'hydrogels heterodisperses - medicaments amorphes a liberation prolongee |
WO1999021534A1 (fr) * | 1997-10-27 | 1999-05-06 | Merck Patent Gmbh | Solutions a l'etat solide et dispersions de medicaments tres faiblement solubles dans l'eau . |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003094895A1 (fr) * | 2002-05-07 | 2003-11-20 | Bernard Charles Sherman | Comprimes a liberation prolongee a base de felodipine |
WO2004028503A1 (fr) * | 2002-09-30 | 2004-04-08 | Universiteit Gent | Systeme a liberation controlee de substances bioactives |
Also Published As
Publication number | Publication date |
---|---|
CN1319004A (zh) | 2001-10-24 |
SE9902742D0 (sv) | 1999-07-20 |
AU3095600A (en) | 2001-02-05 |
JP2003504392A (ja) | 2003-02-04 |
KR20010078703A (ko) | 2001-08-21 |
NO20004816L (no) | 2000-11-02 |
CA2328102A1 (fr) | 2001-01-20 |
EP1113786A1 (fr) | 2001-07-11 |
NO20004816D0 (no) | 2000-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1304294C (fr) | Preparations pharmaceutiques a liberation prolongee | |
US11253523B2 (en) | Tofacitinib oral sustained release dosage forms | |
KR100203339B1 (ko) | 의약용 방출조절 매트릭스 | |
ES2360102T3 (es) | Sistema para la liberación controlada de morfina. | |
AU615211B2 (en) | New pharmaceutical preparation | |
CZ288598B6 (cs) | Třífázová farmaceutická forma s konstantním a řízeným uvolňováním amorfní účinné složky a způsob její přípravy | |
JP2003520772A (ja) | 脂質調節剤を含む新規製剤 | |
WO2002067852A2 (fr) | Formulation pharmaceutique à libération lente | |
WO2007016388A2 (fr) | Formulations liquides pour l'administration controlee des derives de benzisoxazole | |
JP2008534584A (ja) | フェノフィブラート含有メントール又はpeg/ポロキサマー混合物の改良製剤 | |
US6558703B1 (en) | Porous hydroxyapatite particles as carriers for drug substances | |
ES2321908T3 (es) | Preparaciones farmaceuticas de liberacion prolongada independientemente del ph. | |
EP1113786A1 (fr) | Nouvelle formulation pharmaceutique | |
SI8710407A (sl) | Postopek za pridobivanje trdnega pripravka s podaljšanim sproščanjem aktivne spojine | |
JP2000501094A (ja) | 持続放出薬剤送達システム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99811100.7 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09485020 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 30956/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 507191 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999964928 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2328102 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007011312 Country of ref document: KR |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |
Free format text: (EXCEPT AU, CA, CN, JP, KR, NO, NZ, EP (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)) |
|
WWP | Wipo information: published in national office |
Ref document number: 1999964928 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007011312 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999964928 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020007011312 Country of ref document: KR |